MFDA Reissues Permit for Panadol Use and Distribution Following Safety Evaluation

The Maldives Food and Drug Authority (MFDA) has reinstated permission for the use of Panadol medicine today following an evaluation of its safety.

In an announcement issued by the Authority, it was revealed that the results of the investigation into quality fluctuations of the 500 milligram Panadol medicine have been received. The MFDA shared that the report indicated a lack of the required strength in the “Panadol” brand.

advertisement

advertisement

advertisement

The drug authority noted that this fluctuation was attributed to a failure to maintain standards in the transport and storage of the medicine, as observed. MFDA assured that the batch of Panadol with quality issues has been withdrawn from the market.

Panadol is one of the most commonly used medicines in the Maldives. MFDA had imposed restrictions on the importation of this medicine on the 30th of last month after certain samples obtained from the market showed signs of dissolution and chipping around the edges. 

The authority had suspended the sale of these tablets pending further notice. However, after additional assessments and inspections, these measures have been relaxed.